Abstract: Astrocytes are involved in many diseases of the central nervous system, not only as reactive cells to neuronal damage but also as primary actors in the pathological process. Astrogliopathy is a term used to designate the involvement of astrocytes as key elements in the pathogenesis and pathology of diseases and injuries of the central nervous system. Astrocytopathy is utilized to name non-reactive astrogliosis covering hypertrophy, atrophy and astroglial degeneration with loss of function in astrocytes and pathological remodeling, as well as senescent changes. Astrogliopathy and astrocytopathy are hallmarks of tauopathies-neurodegenerative diseases with abnormal hyper-phosphorylated tau aggregates in neurons and glial cells. The involvement of astrocytes covers different disease-specific types such as tufted astrocytes, astrocytic plaques, thorn-shaped astrocytes, granular/fuzzy astrocytes, ramified astrocytes and astrocytes with globular inclusions, as well as others which are unnamed but not uncommon in familial frontotemporal degeneration linked to mutations in the tau gene. Knowledge of molecular differences among tau-containing astrocytes is only beginning, and their distinct functional implications remain rather poorly understood. However, tau-containing astrocytes in certain conditions have deleterious effects on neuronal function and nervous system integrity. Moreover, recent studies have shown that tau-containing astrocytes obtained from human brain tauopathies have a capacity for abnormal tau seeding and spreading in wild type mice. Inclusive conceptions include a complex scenario involving neurons, glial cells and local environmental factors that potentiate each other and promote disease progression in tauopathies.
Introduction
Tauopathies are adult-age clinically, biochemically and anatomically heterogeneous neurodegenerative diseases, defined by the depositing of excessively phosphorylated tau protein, which is abnormally folded and eventually forms aggregates in nerve cells. Tau deposits in nerve cells form neurofibrillary tangles (NFT, neurofibrillary degeneration) and pre-tangle deposits, aggregates in neuronal and glial cell processes form neuropil threads, inclusions in astrocytes give rise to different morphological types, and inclusions in oligodendrocytes mainly form coiled bodies and, rarely, globular inclusions. Certain regions of the brain, and certain cell populations, are vulnerable to the pathology of tau, although the mechanisms of regional vulnerability and selective cellular vulnerability in tauopathies are poorly understood. Tau proteins are encoded by the microtubule-associated protein tau gene MAPT, the transcription of which, by alternative splicing, produces six isoforms in the brain. Some staining; short arrow: cells only stained green; arrowhead: cells only stained red. Hyper-phosphorylated tau-containing astrocytes have reduced GFAP immunoreactivity. Paraffin sections; nuclei (blue) are stained with DRAQ5 (Biostatus, Leicestershire, UK); WM: withe matter; bar = 50 μm. Astrocytic plaques in corticobasal degeneration (CBD), stained with 4Rtau, P-tauThr181, AT8 (P-tau Ser202-Thr205) and antibody PHF1 (P-tauSer396-Ser404). Paraffin sections slightly counterstained with hematoxilin, bar = 25 μm.
However, some tau-containing astrocytes are found in different tauopathies-for example, TSAs occur in aging, AGD, AD, PSP and CBD [14, 19, [67] [68] [69] [70] [71] [72] , and in traumatic chronic staining; short arrow: cells only stained green; arrowhead: cells only stained red. Hyper-phosphorylated tau-containing astrocytes have reduced GFAP immunoreactivity. Paraffin sections; nuclei (blue) are stained with DRAQ5 (Biostatus, Leicestershire, UK); WM: withe matter; bar = 50 μm. Astrocytic plaques in corticobasal degeneration (CBD), stained with 4Rtau, P-tauThr181, AT8 (P-tau Ser202-Thr205) and antibody PHF1 (P-tauSer396-Ser404). Paraffin sections slightly counterstained with hematoxilin, bar = 25 μm.
However, some tau-containing astrocytes are found in different tauopathies-for example, TSAs occur in aging, AGD, AD, PSP and CBD [14, 19, [67] [68] [69] [70] [71] [72] , and in traumatic chronic Astrocytic plaques in corticobasal degeneration (CBD), stained with 4Rtau, P-tauThr181, AT8 (P-tau Ser202-Thr205) and antibody PHF1 (P-tauSer396-Ser404). Paraffin sections slightly counterstained with hematoxilin, bar = 25 µm.
However, some tau-containing astrocytes are found in different tauopathies-for example, TSAs occur in aging, AGD, AD, PSP and CBD [14, 19, [67] [68] [69] [70] [71] [72] , and in traumatic chronic encephalopathy [73] . Granular/fuzzy astrocytes are seen in the elderly and ARTAG [26, 70] , but also in other tauopathies such as in PSP [37] .
Interestingly, tau-containing astrocytes are early lesions in PSP, CBD and FTLD-tau [28, [74] [75] [76] .
Various types of astrocytic inclusions are generated in familial FTLD-tau linked to mutations in exons 1 and 10 and in introns following exons 9 and 10, the morphology of which largely depends on the MAPT mutation. Intracytoplasmic tau-immunoreactive inclusions in FTLD-tau are represented by tufted-like astrocytes, astrocytic plaques, ramified astrocytes, TSAs, astrocytes with globular inclusions and other types with no specific names [17, 33, 34, 36, 37, 66, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] . Tufted astrocytes and astrocytic plaques practically do not co-exist in PSP and CBD [57] , but these lesions appear in combination in FTLD-tau [29] (Figure 4) .
encephalopathy [73] . Granular/fuzzy astrocytes are seen in the elderly and ARTAG [26, 70] , but also in other tauopathies such as in PSP [37] . Interestingly, tau-containing astrocytes are early lesions in PSP, CBD and FTLD-tau [28, [74] [75] [76] . Various types of astrocytic inclusions are generated in familial FTLD-tau linked to mutations in exons 1 and 10 and in introns following exons 9 and 10, the morphology of which largely depends on the MAPT mutation. Intracytoplasmic tau-immunoreactive inclusions in FTLD-tau are represented by tufted-like astrocytes, astrocytic plaques, ramified astrocytes, TSAs, astrocytes with globular inclusions and other types with no specific names [17, 33, 34, 36, 37, 66, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] . Tufted astrocytes and astrocytic plaques practically do not co-exist in PSP and CBD [57] , but these lesions appear in combination in FTLD-tau [29] (Figure 4 ). Extensive astrocyte-predominant tauopathy involving brain astrocytes and Bergmann glia has been reported in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy; the morphology of abnormal astrocytes, including deposits in Bergmann glia, differs from all other tauopathies [87] .
The localization of tau-containing astrocytes does not always match that of tau-containing neurons in tauopathies [14, 19, 28, 76, [88] [89] [90] [91] [92] . Curiously, tufted astrocytes and astrocytic plaques are often located near the blood vessels [93] , and perivascular distribution is overwhelming in a rare familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [87] . Regarding ARTAG, TSAs are found in regions proximal to the CSF and blood vessels [72] .
Hyper-phosphorylated tau intracytoplasmic filamentous inclusions are common in transgenic mouse models of tauopathies both in animals over-expressing human tau and those bearing different tau mutations which are causative of human familial FTLD-tau. Tau pathology in glial cells has been generated in transgenic mice over-expressing human tau in neurons and glial cells. In these animals, a tau pathology resembling astrocytic plaques and coiled bodies in oligodendrocytes is found in old mice; these changes are associated with glial and axonal degeneration [94] .
Transgenic mice bearing P301L tau develop cytoplasmic neuronal inclusions, and oligodendroglial and astrocytic filamentous inclusions composed of abnormal hyper-phosphorylated tau aggregates [95] . Similar neuronal and glial tau-immunoreactive inclusions occur in the P301S transgenic mouse ( Figure 5 ). Extensive astrocyte-predominant tauopathy involving brain astrocytes and Bergmann glia has been reported in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy; the morphology of abnormal astrocytes, including deposits in Bergmann glia, differs from all other tauopathies [87] .
Transgenic mice bearing P301L tau develop cytoplasmic neuronal inclusions, and oligodendroglial and astrocytic filamentous inclusions composed of abnormal hyper-phosphorylated tau aggregates [95] . Similar neuronal and glial tau-immunoreactive inclusions occur in the P301S transgenic mouse ( Figure 5 ). 
Post-Translational Tau Modifications and Tau Kinases in Tau-Containing Astrocytes in Tauopathies
Tau in astrocytes is hyper-phosphorylated at different sites including Thr181, Ser199, Thr231, Ser262, Ser422, Ser202-Thr205 (antibody AT8), Ser396-Ser404 (antibody PHF1) and Thr212/Ser214 (tau-100), and it has an altered conformation as revealed with the antibodies Alz50 (amino acids 5-15) and MC-1 (amino acids 312-322) [37] . All these astrocytic inclusions in sporadic tauopathies are composed of 4Rtau isoforms, but certain astrocytes in PiD and PSP contain 3Rtau [37] . Astrocytic inclusions in FTLD-tau depend on the mutation, but they are largely composed of 4Rtau [33, 37, 66] .
Astrocytes containing hyper-phosphorylated tau inclusions co-express phosphorylated tau kinases: mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), p-38 kinase, stress-activated kinase/c-Jun N-terminal kinase (SAPK/JNK) and glycogen synthase kinase-3 [14, 82, [96] [97] [98] [99] [100] . Co-expression in astrocytes suggests active phosphorylation of tau by specific kinases; such co-localization also occurs in neurons with pre-tangles and tangles in the same tauopathies.
The presence of truncated forms of tau in tau-containing astrocytes is not documented in detail. Most tau-containing astrocytes in tauopathies are not stained with the antibody tau-C3 which recognizes tau truncated at aspartic acid 421 [37] . Only small tau-C3 immunoreactive dots are occasionally seen in TSAs [71] . Exceptions are astrocytes with globular inclusions in GGT, astrocytes in certain FTLD-tau (as in the familial tauopathy linked to MAPT K317M), and astrocytes in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [37, 87] . In such cases, tau-containing astrocytes are always ubiquitinated [37] . In contrast, tufted astrocytes, astrocytic plaques, TSAs and ramified astrocytes only very rarely contain ubiquitin-immunoreactive deposits [37] (Figure 6 ). 
The presence of truncated forms of tau in tau-containing astrocytes is not documented in detail. Most tau-containing astrocytes in tauopathies are not stained with the antibody tau-C3 which recognizes tau truncated at aspartic acid 421 [37] . Only small tau-C3 immunoreactive dots are occasionally seen in TSAs [71] . Exceptions are astrocytes with globular inclusions in GGT, astrocytes in certain FTLD-tau (as in the familial tauopathy linked to MAPT K317M), and astrocytes in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [37, 87] . In such cases, tau-containing astrocytes are always ubiquitinated [37] . In contrast, tufted astrocytes, astrocytic plaques, TSAs and ramified astrocytes only very rarely contain ubiquitin-immunoreactive deposits [37] ( Figure 6 ). Tau phosphorylation, conformation and truncation in astrocytes have characteristics similar to their neuronal counterparts in tauopathies with equivalents to pre-tangles and tangle stages [37] . However, this must be interpreted with caution as knowledge is still limited. For example, a lack of epitopes derived from alternatively spliced exon 2 and 3 has been reported in glial tau when compared with neuronal tau in certain tauopathies [56, 101] . Tau acetylation is rarer in astrocytes when compared to neurons in tauopathies [102] . Tau is acetylated in glial inclusions in FTLD-tau [102] but apparently not in AGD [103] . This is an important point, as tau acetylation inhibits tau function and promotes tau aggregation [104, 105] .
Finally, tau truncation may occur at different sites of tau; western blots of total brain homogenates show bands of low molecular weight in most tauopathies, but the method does not discriminate between neurons and glial cells. Immunohistochemistry utilizing tau antibodies directed against specific amino acids of tau (amino-terminal, carboxyl-terminal, middle segments) can be useful to uncover possible sites of tau truncation in astrocytes in tauopathies in addition to the characteristic truncation at aspartic acid 421 in astrocytes in minority tauopathies. Thorn-shaped astrocytes (TSAs) are stained with antibody 394 (amino acids 394-398, corresponding to the carboxyl-terminal); antibody 229 (against amino acids 229-233, middle region) and antibody 499 (directed against amino acids 14-26, amino-terminal) [106] . Tau-containing astrocytes in FTLD-tau 301T are stained with antibodies tau 7 (directed against amino acids 426-441), 394, 229 and 499 ( Figure 7A ). However, tufted astrocytes in PSP and astrocytic plaques in CBD are decorated with antibodies tau 7, 229 and 394 but barely or not at all with antibody 499, thus suggesting the reduction or absence of tau species containing the amino terminal of tau protein in tufted astrocytes and astrocytic plaques ( Figure 7B,C) . Tau phosphorylation, conformation and truncation in astrocytes have characteristics similar to their neuronal counterparts in tauopathies with equivalents to pre-tangles and tangle stages [37] . However, this must be interpreted with caution as knowledge is still limited. For example, a lack of epitopes derived from alternatively spliced exon 2 and 3 has been reported in glial tau when compared with neuronal tau in certain tauopathies [56, 101] . Tau acetylation is rarer in astrocytes when compared to neurons in tauopathies [102] . Tau is acetylated in glial inclusions in FTLD-tau [102] but apparently not in AGD [103] . This is an important point, as tau acetylation inhibits tau function and promotes tau aggregation [104, 105] .
Finally, tau truncation may occur at different sites of tau; western blots of total brain homogenates show bands of low molecular weight in most tauopathies, but the method does not discriminate between neurons and glial cells. Immunohistochemistry utilizing tau antibodies directed against specific amino acids of tau (amino-terminal, carboxyl-terminal, middle segments) can be useful to uncover possible sites of tau truncation in astrocytes in tauopathies in addition to the characteristic truncation at aspartic acid 421 in astrocytes in minority tauopathies. Thorn-shaped astrocytes (TSAs) are stained with antibody 394 (amino acids 394-398, corresponding to the carboxyl-terminal); antibody 229 (against amino acids 229-233, middle region) and antibody 499 (directed against amino acids 14-26, amino-terminal) [106] . Tau-containing astrocytes in FTLD-tau 301T are stained with antibodies tau 7 (directed against amino acids 426-441), 394, 229 and 499 ( Figure 7A ). However, tufted astrocytes in PSP and astrocytic plaques in CBD are decorated with antibodies tau 7, 229 and 394 but barely or not at all with antibody 499, thus suggesting the reduction or absence of tau species containing the amino terminal of tau protein in tufted astrocytes and astrocytic plaques ( . Double-labeling immunofluorescence and confocal microscopy using antibodies tau 7 (directed against amino acids 426-441), 394 (amino acids 394-398, corresponding to the carboxyl terminal), 229 (against amino acids 229-233, middle region), and 499 (directed against amino acids 14-26, amino terminal) (green); and P-tauThr181 or AT8 (depending on the mouse or rabbit origin of the first anti-tau antibodies) (red) in FTLD-tau linked to 301T mutation (A); PSP (B) and CBD (C). Tau 7, 229 and 394 co-localize with phospho-tau deposits in astrocytes in FTLD-tau 301T, tufted astrocytes and astrocytic plaques; antibody 499 also co-localizes with phospho-tau in FTLD-tau 301T, but tufted astrocytes and astrocytic plaques almost lack 499 tau immunostaining, thus suggesting tau amino terminal truncation. Paraffin sections; nuclei (blue) are stained with DRAQ5 (Biostatus); A, bar= 20 μm; B, bar = 25 μm C; bar = 30 μm.
Cytoarchitectonic Changes Linked to Tau Deposits in Astrocytes
Not all astrocytes are immunoreactive to glial fibrillary acidic protein (GFAP) [107] [108] [109] [110] . However, GFAP is currently used as a marker of astrocytes, mainly for reactive astrocytes.
Even considering these limitations, double-labeling immunofluorescence and confocal microscopy have been used to learn about cytoskeletal anomalies in astrocytes containing hyper-phosphorylated tau. Glial fibrillary acidic protein has been reported to be absent in tufted astrocytes in PSP [58, 111] . However, small amounts of GFAP are commonly redistributed around the nucleus in tufted astrocytes in PSP and FTLD-tau. GFAP is disrupted by short segments or dots of hyper-phosphorylated tau throughout the astrocytic processes in astrocytic plaques in CBD, and in astrocytes with proximal granular inclusions in FTLD-tau/P301L. Glial fibrillary acidic protein immunoreactivity is also displaced by hyper-phosphorylated tau deposits in ramified astrocytes in PiD, TSAs in ARTAG, tau-containing astrocytes in GGT, and astrocytes in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [37, 87, 92] (Figure 8 ). . Double-labeling immunofluorescence and confocal microscopy using antibodies tau 7 (directed against amino acids 426-441), 394 (amino acids 394-398, corresponding to the carboxyl terminal), 229 (against amino acids 229-233, middle region), and 499 (directed against amino acids 14-26, amino terminal) (green); and P-tauThr181 or AT8 (depending on the mouse or rabbit origin of the first anti-tau antibodies) (red) in FTLD-tau linked to 301T mutation (A); PSP (B) and CBD (C). Tau 7, 229 and 394 co-localize with phospho-tau deposits in astrocytes in FTLD-tau 301T, tufted astrocytes and astrocytic plaques; antibody 499 also co-localizes with phospho-tau in FTLD-tau 301T, but tufted astrocytes and astrocytic plaques almost lack 499 tau immunostaining, thus suggesting tau amino terminal truncation. Paraffin sections; nuclei (blue) are stained with DRAQ5 (Biostatus); A, bar= 20 µm; B, bar = 25 µm C; bar = 30 µm.
Even considering these limitations, double-labeling immunofluorescence and confocal microscopy have been used to learn about cytoskeletal anomalies in astrocytes containing hyper-phosphorylated tau. Glial fibrillary acidic protein has been reported to be absent in tufted astrocytes in PSP [58, 111] . However, small amounts of GFAP are commonly redistributed around the nucleus in tufted astrocytes in PSP and FTLD-tau. GFAP is disrupted by short segments or dots of hyper-phosphorylated tau throughout the astrocytic processes in astrocytic plaques in CBD, and in astrocytes with proximal granular inclusions in FTLD-tau/P301L. Glial fibrillary acidic protein immunoreactivity is also displaced by hyper-phosphorylated tau deposits in ramified astrocytes in PiD, TSAs in ARTAG, tau-containing astrocytes in GGT, and astrocytes in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [37, 87, 92] (Figure 8 ). 
Astrogliopathy
This term refers to alterations of astrocytes occurring in diseases of the nervous system, implying the involvement of astrocytes as key elements in the pathogenesis and pathology of diseases and in injuries of the central nervous system [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] .
Reactive astrogliosis is a reaction secondary to neuronal damage in various injuries such as trauma and ischemia, external toxins, metabolic disorders and neurodegenerative diseases. The term astrocytopathy is used for non-reactive astrogliosis including hypertrophy, atrophy and astroglial degeneration with loss of function manifested by variable and distinct molecular changes in astrocytes, and pathological remodeling [112, 117] . Senescent astrocytes are a particular form of astrocytophathy linked to old age which is manifested by modifications in the morphology of the nucleus and cytoplasm, cytoskeletal changes, oxidative damage, reduced energy production and secretory phenotype including production of inflammatory cytokines [92] .
Reactive Astrogliosis
Reactive astrogliosis is common to all tauopathies and its distribution correlates with the degree of regional vulnerability to neuronal degeneration and neuronal loss [17, 123, 124] . However, tau-containing astrocytes do not match reactive astrocytes and they represent different although occasionally co-existent lesions [17, 18, 92, 124] .
Reactive astrogliosis also occurs in transgenic mouse models; the hippocampus is mainly affected in mice bearing the P301S mutation [125] .
The expression of small heat shock proteins (HSP25/27 and αB-crystallin) is a characteristic response of reactive astrocytes in most tauopathies. However, HSPs are rarely co-expressed in astrocytes containing hyper-phosphorylated tau [126] [127] [128] [129] (Figure 9 ). This suggests that generalized stress, rather than the restricted response in glial cells with abnormal protein aggregates, induces HSP expression [129] . Alternatively, it may be postulated that stress responses are directed to correcting protein misfolding, and that they succeed to a certain extent, in that aggregates are not formed in many glial cells [92] . 
Astrogliopathy
Reactive Astrogliosis
The expression of small heat shock proteins (HSP25/27 and αB-crystallin) is a characteristic response of reactive astrocytes in most tauopathies. However, HSPs are rarely co-expressed in astrocytes containing hyper-phosphorylated tau [126] [127] [128] [129] (Figure 9 ). This suggests that generalized stress, rather than the restricted response in glial cells with abnormal protein aggregates, induces HSP expression [129] . Alternatively, it may be postulated that stress responses are directed to correcting protein misfolding, and that they succeed to a certain extent, in that aggregates are not formed in many glial cells [92] . Additionally, it has been reported that intraneuronal accumulation of misfolded tau protein induces over-expression of Hsp27 in activated astrocytes [130] . 
Astrocytopathy
In spite of the evident astrocytopathy characterized by disease-dependent stereotyped tau deposits, little is known about the functional effects of hyper-phosphorylated tau in tau-containing astrocytes in tauopathies [131] . This is due to several factors: the diversity of astrocytes, diversity of functions and gene expression profiles under various conditions and regions, as well as the lack of studies considering these variables in tauopathies.
Astrocytes are not homogeneous cells. They can be classified into protoplasmic astrocytes of the grey matter, interlaminar astrocytes of the cerebral cortex, subpial astrocytes of the cerebral cortex, fibrous astrocytes of the white matter, perivascular astrocytes, Bergmann glia, stem astrocytes of subventricular zones, radial glia of the developing brain, tanycytes of the hypothalamus, pituicytes and Müller glia of the retina [116] . Moreover, they are heterogeneous with respect to their coverage domains, ion channels, calcium responses, glutamate transporters and expression of neurotransmitter receptors [92, 132] .
Gene expression studies of neurons and glial cells have contributed to our understanding of the variety of gene expression profiles that advance distinct functions in different cell types [133] [134] [135] [136] [137] [138] [139] [140] . Microarray analyses of isolated astrocytes have identified particular transcription profiles in AD and related animal models [141, 142] .
Unfortunately, this approach has not been utilized in human tauopathies, and we are still in the dark concerning gene expression differences among TSAs, tufted astrocytes, astrocytic plaques and astrocytes with globular inclusions, to name just some examples.
Moreover, we do not know about similarities and differences among tau-containing astrocytes in the same disease but located in different regions; for example, subependymal, subpial, clusters in the frontal and temporal white matter, basal forebrain and perivascular TSAs in ARTAG.
These aspects are important in the present context as we do not know whether different tau inclusions affect different astrocyte types with particular vulnerability to tau species, or even if different tau species modify the morphology and function of the same type of astrocyte.
The over-expression of tau in cultured astrocytes produces degeneration of the cytoskeleton and Golgi complex, eventually leading to cell death [143] . Altered nuclear function and DNA transcription has also been posited for tau-containing neurons in tauopathies and fly models [144] [145] [146] [147] . Additionally, it has been reported that intraneuronal accumulation of misfolded tau protein induces over-expression of Hsp27 in activated astrocytes [130] .
The over-expression of tau in cultured astrocytes produces degeneration of the cytoskeleton and Golgi complex, eventually leading to cell death [143] . Altered nuclear function and DNA transcription has also been posited for tau-containing neurons in tauopathies and fly models [144] [145] [146] [147] .
The expression of solute carrier family 1 member 2 (SLC1A2 or GLT-1) is markedly reduced in most astrocytes bearing hyper-phosphorylated tau in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [87] . Decreased expression of GLT-1 and solute carrier family 1 member 3 (SLC1A3 or GLAST) also occurs in transgenic mice selectively expressing hyper-phosphorylated tau in astrocytes [148, 149] .
Whether tau-containing astrocytes have deleterious effects on neurons is an important question, as decreased GLT-1 expression alters glutamate metabolism and enhances excitoxicity. Hyper-phosphorylated tau deposits also have effects on the redistribution of organelles and reactive responses, but their functional effects are not known (Figure 10 ). The expression of solute carrier family 1 member 2 (SLC1A2 or GLT-1) is markedly reduced in most astrocytes bearing hyper-phosphorylated tau in familial behavioral variant frontotemporal dementia associated with astrocyte-predominant tauopathy [87] . Decreased expression of GLT-1 and solute carrier family 1 member 3 (SLC1A3 or GLAST) also occurs in transgenic mice selectively expressing hyper-phosphorylated tau in astrocytes [148, 149] .
Whether tau-containing astrocytes have deleterious effects on neurons is an important question, as decreased GLT-1 expression alters glutamate metabolism and enhances excitoxicity. Hyper-phosphorylated tau deposits also have effects on the redistribution of organelles and reactive responses, but their functional effects are not known (Figure 10 ). Figure 10 . Double-labeling immunofluorescence and confocal microscopy of tufted astrocytes in PSP to AT8 and voltage-dependent anion-selective channel 1: VDAC1 (upper row), AT8 and superoxide dismutase 2: MnSOD, SOD2 (middle row), and serial sections of P-tauThr181 and αB-crystallin (lower row). VDAC1 is concentrated at the center of the cell due to the displacement of peripheral tau whereas SOD2 immunoreactivity is intermingled with phospho-tau deposits. αB-crystallin is found around the nucleus and surrounded by hyper-phosphorylated tufts. Paraffin sections; nuclei (blue) are stained with DRAQ5 (Biostatus); upper row, bar =20 μm; middle and lower row, bar =8μm.
Moreover, extracellular tau oligomers rapidly accumulate in astrocytes and reduce the release of gliotransmitters, thus impairing neuronal function [150] .
Furthermore, FTLD-N279K MAPT astrocytes derived from neural stem cells increase oxidative stress and produce marked modifications in the genomic expression of co-cultured healthy neurons [151] . Finally, P301S-derived astrocytes significantly decrease pre-synaptic and post-synaptic protein expression in cortical neuron cultures, whereas normal astrocytes enhance these markers, thereby suggesting that mutant astrocytes have reduced neuroprotective capacities [152] . Figure 10 . Double-labeling immunofluorescence and confocal microscopy of tufted astrocytes in PSP to AT8 and voltage-dependent anion-selective channel 1: VDAC1 (upper row), AT8 and superoxide dismutase 2: MnSOD, SOD2 (middle row), and serial sections of P-tauThr181 and αB-crystallin (lower row). VDAC1 is concentrated at the center of the cell due to the displacement of peripheral tau whereas SOD2 immunoreactivity is intermingled with phospho-tau deposits. αB-crystallin is found around the nucleus and surrounded by hyper-phosphorylated tufts. Paraffin sections; nuclei (blue) are stained with DRAQ5 (Biostatus); upper row, bar =20 µm; middle and lower row, bar =8µm.
Disease Progression: Seeding and Spreading; Role of Astrocytes
Furthermore, FTLD-N279K MAPT astrocytes derived from neural stem cells increase oxidative stress and produce marked modifications in the genomic expression of co-cultured healthy neurons [151] . Finally, P301S-derived astrocytes significantly decrease pre-synaptic and post-synaptic protein expression in cortical neuron cultures, whereas normal astrocytes enhance these markers, thereby suggesting that mutant astrocytes have reduced neuroprotective capacities [152] .
Tauopathies are progressive biological processes with a preclinical phase, prodromal phases and phases with clinical manifestations. The stages of NFT progression (stages I-VI of Braak) in AD are well known [153, 154] . The stages of NFT pathology in PART are the same as those proposed for AD; whether PART is part of AD is a matter of discussion [155, 156] . The majority of cases formerly classified as early stages of sporadic AD lack Aβ plaques [157, 158] and are now considered PART, whereas the majority of cases with advanced Braak NFT stages are considered AD because of the presence of abundant Aβ deposits. Whatever the name, early stages of NFT are very common in old people as they occur in about 85% of individuals aged 65 years [157, 159] .
Different stages have also been proposed to categorize disease progression in AGD [14, 160] . In contrast, only short series of incidental and early stages of PSP and CBD are available [74] [75] [76] 161, 162] to permit a validation of the several proposed sequences of events in disease progression.
The progression of AD and tauopathies is thought to occur by trans-cellular and trans-regional propagation of the abnormal protein in a similar way to what happens in prion diseases [163] . The exact mechanism of transmission is not known. Release and trans-synaptic transmission of tau [164, 165] , tau uptake via exosomes [166] [167] [168] or nanotubules [169] and free uptake of fibrillar proteins [170, 171] have all been suggested as putative mechanisms using cultured neurons. Although astrocyte-to-neuron intercellular transfer mediated by cell-to-cell contact has been postulated for prions [172] , no information is available concerning astrocyte-to-neuron transfer in tauopathies.
Transgenic mice with human tau over-expression or with tau mutations have been used to facilitate the mechanism of seeding and progression. Seeding and spreading of abnormal tau occurs after inoculation of brain homogenates from AD and other tauopathies into the brain of transgenic mice over-expressing human tau or mutated tau [163, [173] [174] [175] . The type of deposits in the inoculated animals seems to be disease-dependent in the few tauopathies so far studied, which suggests the occurrence of different species or strains of tau depending on the disease [176] [177] [178] . However, these models have a natural substrate of abnormal tau production that makes it difficult to separate the propagation itself from what is induced.
Seeding of human tau from homogenates of AD and tauopathies with neuronal and glial components is also observed after inoculation into the brain of wild-type mice [178, 179] .
Additionally, the inoculation effect of recombinant tau is different from the effects using human brain homogenates enriched with tau fibrils from brains with tauopathy [178] . This suggests that different species ('strains') of tau have different properties and produce different effects. Another difference between the inoculation of recombinant tau fibrils and inoculation of tau from human brain homogenates is the accompanying inoculation, in the latter, of a number of associated proteins and enzymes which represents a probably disease-specific environment with unexplored properties.
All these experiments have been performed using brain samples of tauopathies with tau pathology only in neurons or with tau pathology in neurons and in glial cells. Abnormal tau in these paradigms can spread to resident neurons, astrocytes and oligodendroglia [176] [177] [178] . In other words, certain tau prion strains have the capacity to induce tauopathy not only in neurons but also in glial cells [180] ( Figure 11 ). Whether astrocytic tau alone is able to induce tauopathy has recently been assessed. Tau-enriched fractions of brain homogenates from pure ARTAG (with no associated tauopathy) inoculated into the hippocampus (dentate gyrus and cornu ammonis (CA1) of wild-type mice generate intracytoplasmic hyper-phosphorylated tau inclusions in astrocytes, oligodendrocytes and neurons near the site of injection, and in nerve fiber tracts in the fimbria and corpus callosum [106] ( Figure 12 ). These observations indicate that astrocytes containing hyper-phosphorylated tau have the capability of seeding tau to neurons and glial cells, thus highlighting the putatively cardinal role of astrocytopathy in the pathogenesis of tauopathies [106] . Moreover, inoculation of ARTAG, containing 4Rtau astrocytes, produces 3Rtau seeding in neurons and glial cells in addition to 4Rtau deposition [106] . This also points to the likely involvement of astrocytes in the development of tau-containing neuronal processes in the aged brain [181] . Figure 11 . Wild-type (WT) mice inoculated with primary age-related tauopathy (PART) in the hippocampus at the age of 7 months and killed at the age of 10 months. Double-labeling immunofluorescence to neuronal nuclear protein (NeuN), GFAP and Olig-2 (green) and P-tauThr181 or clone AT8 (red). Subpopulations of neurons, astrocytes and oligodendrocytes contain hyper-phosphorylated tau (arrows). Paraffin sections, nuclei stained with DRAQ5 (Biostatus) (blue), bar, upper and middle row, bar = 30 µm; lower row, bar = 40 µm.
Whether astrocytic tau alone is able to induce tauopathy has recently been assessed. Tau-enriched fractions of brain homogenates from pure ARTAG (with no associated tauopathy) inoculated into the hippocampus (dentate gyrus and cornu ammonis (CA1) of wild-type mice generate intracytoplasmic hyper-phosphorylated tau inclusions in astrocytes, oligodendrocytes and neurons near the site of injection, and in nerve fiber tracts in the fimbria and corpus callosum [106] (Figure 12 ). These observations indicate that astrocytes containing hyper-phosphorylated tau have the capability of seeding tau to neurons and glial cells, thus highlighting the putatively cardinal role of astrocytopathy in the pathogenesis of tauopathies [106] . Moreover, inoculation of ARTAG, containing 4Rtau astrocytes, produces 3Rtau seeding in neurons and glial cells in addition to 4Rtau deposition [106] . This also points to the likely involvement of astrocytes in the development of tau-containing neuronal processes in the aged brain [181] . The fact that a neuronal tauopathy such as PART (only containing NFTs and threads) or pure forms of ARTAG (only containing TSAs) can produce seeding in neurons, astrocytes and oligodendrocytes in WT mice is an unexpected observation. This may be in part because different murine tau isoforms can be distinguished by the carboxyl terminal domains, and murine tau differs from human tau in a number of ways, including the absence of residues which are involved in tubulin binding [182] .
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